anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (V H H) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.
Participants will receive 6 mg dexamethasone daily for 10 days, then 8 mg dexamethasone daily for 4 weeks with a 2-week taper. Participants will also receive albendazole and omeprazole.
Systems and methods for generating a virtual gingiva. The method includes receiving, by one or more processors, a first three-dimensional (3D) representation of a dentition. The 3D representation includes a plurality of tooth representations and a gingiva representation. The method includes identifying, by the one or more processors, a shape of the gingiva representation. The method includes generating, by the one or more processors, virtual gingiva having a surface contour based on the shape of the gingiva representation. The method includes generating, by the one or more processors, a second 3D representation comprising the virtual gingiva and the plurality of tooth representations.
AIMS: Atrial fibrillation (AF) symptom relief is a primary indication for catheter ablation, but AF symptom resolution is not well characterized. The study objective was to describe AF symptom documentation in electronic health records (EHRs) pre- and post-ablation and identify correlates of post-ablation symptoms.
METHODS AND RESULTS: We conducted a retrospective cohort study using EHRs of patients with AF (n = 1293), undergoing ablation in a large, urban health system from 2010 to 2020. We extracted symptom data from clinical notes using a natural language processing algorithm (F score: 0.81). We used Cochran's Q tests with post-hoc McNemar's tests to determine differences in symptom prevalence pre- and post-ablation. We used logistic regression models to estimate the adjusted odds of symptom resolution by personal or clinical characteristics at 6 and 12 months post-ablation. In fully adjusted models, at 12 months post-ablation patients, patients with heart failure had significantly lower odds of dyspnoea resolution [odds ratio (OR) 0.38, 95% confidence interval (CI) 0.25-0.57], oedema resolution (OR 0.37, 95% CI 0.25-0.56), and fatigue resolution (OR 0.54, 95% CI 0.34-0.85), but higher odds of palpitations resolution (OR 1.90, 95% CI 1.25-2.89) compared with those without heart failure. Age 65 and older, female sex, Black or African American race, smoking history, and antiarrhythmic use were also associated with lower odds of resolution of specific symptoms at 6 and 12 months.
CONCLUSION: The post-ablation symptom patterns are heterogeneous. Findings warrant confirmation with larger, more representative data sets, which may be informative for patients whose primary goal for undergoing an ablation is symptom relief.
Folic acid, as a one-carbon unit transferase coenzyme, participates in the synthesis of purine and thymine, and is an important element of the nervous system. Vitamin B12 participates in methyl conversion and folate metabolism in the body, promoting the conversion of 5-methyltetrahydrofolate to tetrahydrofolate. It has been reported that the lack of serum folic acid and B12 is associated with an increased risk of cognitive impairment. The explanation mechanism of the relationship between folic acid deficiency and cognitive dysfunction may be that folic acid deficiency leads to impaired central nervous system methylation, resulting in insufficient methyl synthesis of myelin sheaths, neurotransmitters, membrane phospholipids and deoxyribonucleic acid. Our previous studies showed that preoperative folic acid supplementation can alleviate myelin damage and cognitive impairment in young rats caused by sevoflurane anesthesia. Therefore, this study further explored the preoperative folic acid and coenzyme B12 supplementation for children's delirium and long-term neurobehavioral changes after general anesthesia.
AIMS: Cardioneuroablation (CNA) is a catheter-based intervention for recurrent vasovagal syncope (VVS) that consists in the modulation of the parasympathetic cardiac autonomic nervous system. This survey aims to provide a comprehensive overview of current CNA utilization in Europe.
METHODS AND RESULTS: A total of 202 participants from 40 different countries replied to the survey. Half of the respondents have performed a CNA during the last 12 months, reflecting that it is considered a treatment option of a subset of patients. Seventy-one per cent of respondents adopt an approach targeting ganglionated plexuses (GPs) systematically in both the right atrium (RA) and left atrium (LA). The second most common strategy (16%) involves LA GP ablation only after no response following RA ablation. The procedural endpoint is frequently an increase in heart rate. Ganglionated plexus localization predominantly relies on an anatomical approach (90%) and electrogram analysis (59%). Less utilized methods include pre-procedural imaging (20%), high-frequency stimulation (17%), and spectral analysis (10%). Post-CNA, anticoagulation or antiplatelet therapy is prescribed, with only 11% of the respondents discharging patients without such medication. Cardioneuroablation is perceived as effective (80% of respondents) and safe (71% estimated <1% rate of procedure-related complications). Half view CNA emerging as a first-line therapy in the near future.
CONCLUSION: This survey offers a snapshot of the current implementation of CNA in Europe. The results show high expectations for the future of CNA, but important heterogeneity exists regarding indications, procedural workflow, and endpoints of CNA. Ongoing efforts are essential to standardize procedural protocols and peri-procedural patient management.
AIM: The optimal management of patients with clinical complete response after neoadjuvant treatment for rectal cancer is controversial. The aim of this study is to compare the morbidity between patients with locally advanced rectal cancer who have had a pathological complete response (pCR) or not after neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME). The study hypothesis was that pCR may impact the surgical complication rate.
METHOD: A retrospective cohort study was conducted of a prospectively maintained database in Australia and New Zealand, the Binational Colorectal Cancer Audit, that identified patients with locally advanced rectal cancer (<15 cm from anal verge) from 1 January 2007 to 31 December 2019. Patients were included if they had locally advanced rectal cancer and had undergone NCRT and proceeded to surgical resection.
RESULTS: There were 4584 patients who satisfied the inclusion criteria, 65% being male. The mean age was 63 years and 11% had a pCR (ypT0N0). TME with anastomosis was performed in 67.8% of patients, and the majority of the cohort received long-course radiotherapy (81.7%). Both major and minor complications were higher in the TME without anastomosis group (17.3% vs. 14.7% and 30.6% vs. 20.8%, respectively), and the 30-day mortality was 1.31%. In the TME with anastomosis group, pCR did not contribute to higher rates of surgical complications, but male gender (p < 0.0012), age (p < 0.0001), preoperative N stage (p = 0.0092) and American Society of Anesthesologists (ASA) score ≥3 (p < 0.0002) did. In addition, pCR had no significant effect (p = 0.44) but male gender (p = 0.0047) and interval to surgery (p = 0.015) contributed to higher rates of anastomotic leak. In the TME without anastomosis cohort, the only variable that contributed to higher rates of complications was ASA score ≥3 (p = 0.033).
CONCLUSION: Patients undergoing TME dissection for rectal cancer following NCRT showed no difference in complications whether they had achieved pCR or not.
An artificial urinary sphincter can include a cuff configured to surround a portion of a length of a urethra. An actuator is configured to selectively apply a force to the cuff to thereby apply variable amount of pressure to the urethra. A controller is configured to adjust the application of the force by the actuator to cause the cuff to apply the variable amount of pressure to the urethra. A sensor can be in communication with the controller and configured to detect pressure applied against the cuff by the urethra. The controller is configured to cause the cuff to apply a first closing pressure to the urethra. In response to a detection of a threshold pressure increase by the sensor, the controller is configured to cause the cuff to apply a second closing pressure that is greater than the first closing pressure and that prevents urine from exiting the urethra.
Hypertension occurred in 73% of patients in SELECT (DTC) receiving LENVIMA 24 mg orally once daily and in 45% of patients in REFLECT (HCC) receiving LENVIMA 8 mg or 12 mg orally once daily. The median time to onset of new or worsening hypertension was 16 days in SELECT and 26 days in REFLECT. Grade 3 hypertension occurred in 44% of patients in SELECT and in 24% in REFLECT. Grade 4 hypertension occurred <1% in SELECT and Grade 4 hypertension was not reported in REFLECT.

In patients receiving LENVIMA 18 mg orally once daily with everolimus in Study 205 (RCC), hypertension was reported in 42% of patients and the median time to onset of new or worsening hypertension was 35 days. Grade 3 hypertension occurred in 13% of patients. Systolic blood pressure ≥160 mmHg occurred in 29% of patients and diastolic blood pressure ≥100 mmHg occurred in 21% [see Adverse Reactions (6.1)].

Serious complications of poorly controlled hypertension have been reported.

Control blood pressure prior to initiating LENVIMA. Monitor blood pressure after 1 week, then every 2 weeks for the first 2 months, and then at least monthly thereafter during treatment. Withhold and resume at a reduced dose when hypertension is controlled or permanently discontinue LENVIMA based on severity [see Dosage and Administration (2.7)].
ML-004 is a bilayer immediate-release (IR)/extended-release (ER, gastroretentive) oral tablet formulation. ML-004 is taken orally once daily and provided as a tablet in two dose strengths of 12 mg (3 mg IR/9 mg ER) and 24 mg tablet (6 mg IR/18 mg ER). Dose levels for this study are 12 mg (provided as one 12 mg tablet), 24 mg (one 24 mg tablet), 48 mg (two 24 mg tablets), and 72 mg (three 24 mg tablets).
The invention relates to a medical field, in particular to a 'hypochlorous oxidation oral liquid for oral administration'. The invention uses a strong oxidizing property of nascent oxygen generated by chemical reaction of chlorine and water to remove bacteria and viruses in human bodies. With a strong smell and a simulative property, hypochlorous, when taken orally and alone, can stimulate and cause damages to oral cavity, esophagus, gastric mucosa, etc. Therefore, hypochlorous with a concentration in a certain range can not be taken orally. The invention mainly provides a method for taking the hypochlorous. The method comprises the following steps: pouring boiling water into and fully dissolving a certain amount of brown sugar, honey, milk, etc.; when the liquid is cool enough as to not burn the mouth, adding a certain number of chlorine dissection tablets or a certain amount of bleaching powder with complete stirring; and taking orally. The brown sugar, honey, milk can protect the oral cavity, the esophagus and the gastric mucosa against the simulation of the hypochlorous and can reduce the smell of the hypochlorous. The hypochlorous oxidation oral liquid for oral administration of the invention is used to remove bacteria and viruses in the human bodies by the strong oxidizing property of the hypochlorous. With a proper dosage, the hypochlorous oxidation oral liquid for oral administration can realize the prevention and treatment of diseases with side effect caused by chlorine to the human bodies.
The invention provides a method (1) for preparing medicinal liquor. The method comprises a component ratio, a production and a using method. 1. The component ratio is as follows: 580g of tuber fleece-flower roots, 120g of Chinese angelica, 100g of Chinese wolfberry fruits, 80g of dried longan pulp, 30g of gingers, 80g of honey, 15g of ophiopogon roots, 3kg of glutinous rice, 20g of red dates, and 3g of eucommia barks; 2. the production method comprises the following steps: (1). the tuber fleece-flower roots are boiled with water and smashed, and the gingers are juiced for standby; (2). the Chinese angelica, the Chinese wolfberry fruits, the dried longan pulp, the ophiopogon roots, and the red dates are smashed into crude powder, and the crude powder and the tuber fleece-flower roots are sealed in a cloth bag for standby; (3). 2500ml of water is added into the glutinous rice, and the rice is boiled into congee state with slow fire and stored in a jar; (4). after the congee is cooled, the ginger juice is added with uniform stirring, and the congee is sealed; (5). fine powder of the eucommia barks is placed into vinasse with uniform stirring, and the vinasse is sealed for 4-6 days and opened; (6). vinasse dregs are removed, the wine is placed in a jar, and the cloth bag is placed into the wine; (7). the wine jar is heated with water bath for 1.5 hours and is imbedded in soil; (8). after 5 days, the wine is taken out, the cloth bag is removed, and the honey is poured into the wine; 3. the drinking method is as follows: the wine is warmed, 15-20ml of wine can be drunk one time for empty stomach, and the wine is drunk twice a day.
Participants will receive OCA matching placebo orally once weekly or twice weekly for the duration of at least 48-weeks. Participants, who complete their 48-week treatment, can continue the treatment until all randomized participants complete their 48-week treatment period and the database for that period is locked (total duration: approximately up to 3 years).
A care system is provided. The care system is suitably applied to a person under care. The system determines the person’s physiological condition through peripheral sensors. The system determines the health condition of the person under care by monitoring his sleep disorder. The system uses an audio receiver to receive sound about the person under care and obtains the sound of the person after eliminating background audio. The system uses an image sensor to capture the person’s images for motion detection, and obtains posture images of the person. In an aspect, an artificial intelligence technology is introduced to the system for establishing a care-warning prediction model when learning various data including data generated by physiological and environmental sensors. The care-warning prediction model is used to determine if condition of the person under care reaches a warning threshold.
Ribavirin? is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin? is used to suppress Th2-mediated T cell responses and promote Th1mediated T cell response. In other aspects of the invention, one or more Ribavirin? analogs are administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. The Ribavirin? analog(s) may be used to suppress or enhance Th1 or Th2-mediated T cell responses.
Organophosphate pesticides are widely used; however, their use is limited due to neurotoxicity and, to a lesser extent, cardiotoxicity in humans. Given the high energy demands of cardiac muscle, which is characterized by a dense population of mitochondria, any damage to these organelles can exacerbate cardiotoxicity. This study aims to elucidate whether the cardiotoxic effects of organophosphate pesticides originate from mitochondrial dysfunction. To investigate this, in silico toxicogenomic analyses were performed using various tools, such as the Comparative Toxicogenomic Database, GeneMANIA, STRING, and Cytoscape. Results revealed that 11 out of the 13 WHO-recommended Class Ia organophosphate pesticides target genes associated with cardiotoxicity. Notably, three of these genes were mitochondrial, with catalase (CAT) being the common differentially expressed gene among parathion, methyl parathion, and phorate. Furthermore, protein-protein interaction analysis indicated a strong association between CAT and superoxide dismutase 2, mitochondrial (SOD2). Subsequently, isolated heart mitochondria were utilized to assess CAT and superoxide dismutase (SOD) activities in vitro. The findings demonstrated that at a concentration of 7.5 ng/µL, both methyl parathion and phorate significantly decreased CAT activity by approximately 35%. Moreover, phorate reduced total SOD and SOD2 activities by 17% and 19%, respectively, at the same concentration. In contrast, none of the three organophosphate pesticides induced the opening of the mitochondrial permeability transition pore. These results suggest that the reduction in CAT and SOD2 activities, critical antioxidant enzymes, leads to the accumulation of reactive oxygen species within mitochondria, ultimately resulting in mitochondrial damage. This mechanism likely underlies the observed cardiotoxicity induced by these organophosphate pesticides.
The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
The invention discloses blueberry alcohol effect-dispelling and liver-protecting granules and a production method. The blueberry alcohol effect-dispelling and liver-protecting granules are prepared from main raw materials including blueberry, euphorbia kansui, cyrtomium fortunei, hovenia dulcis thumb, pueraria flower, galangal, cardamom, mentha haplocalyx, green tangerine peel, radix puerariae and sandalwood. The production method of the blueberry alcohol effect-dispelling and liver-protecting granules comprises the main processing procedures of material selection, drying, batching, soaking, packaging, and formation of a finished product. The blueberry alcohol effect-dispelling and liver-protecting granules disclosed by the invention have the advantages of caring health, dispelling the effect of the alcohol, soothing the liver, becoming effective rapidly, being absolutely natural and causing no toxic and side effects, etc. The blueberry alcohol effect-dispelling and liver-protecting granules have a good auxiliary treatment effect on main symptoms including vomiting, dizziness and the like. The invention provides the blueberry alcohol effect-dispelling and liver-protecting granules suitable for drinking, and the production method thereof.
Provided is a program connected to a fingernail via a smartphone. A camera module which senses a shape and color of a fingernail collects images, a blood flow rate, an oxygen saturation sensor, a reflection speed of the light, and the like. Based on the collected information, the program analyzes data such as a fingernail color and a fingernail shape related to diseases in a database using artificial intelligence. The program predicts a disease of a user by analyzing patterns repeatedly found in data according to underlying conditions and disease and health status by collecting the overall shape, color, and temperature of a fingernail and changes in the speed of blood from data collected through fingernail detection sensors to data on a temperature of a fingernail bed and a temperature at the outside of the fingernail. In addition, provided is an application, wherein when a disease is predicted, the application is not limited to the prediction, but is connected to a related medical specialist, a special hospital, and a nail shop and thus can provide periodic feedback on the status and health improvement status. According to the present invention, it is possible to easily diagnose diseases according to shapes and colors of fingernails.
Ischemic cholangiopathy (IC) is the leading cause of inferior long-term outcomes following donation after circulatory death (DCD) liver transplant. Biliary strictures related to IC are nonanastomotic strictures (NASs) by definition and involve the donor hepatic ducts proximal to the anastomosis, compared with postsurgical anastomotic strictures that form due to fibrotic healing. IC-related NASs can be microangiopathic with patent hepatic artery or macroangiopathic with occluded or stenotic hepatic artery. Recently, IC with NASs have been described to have four distinct patterns at imaging: diffuse necrosis, multifocal progressive, confluence dominant, and minor form, which correlate clinically with graft prognosis. Severe IC can lead to ductal wall breakdown with subsequent bile leaks that can cause significant patient morbidity, with imaging playing a vital role in diagnosis and guiding intervention. IC also predisposes the transplanted liver to biliary stasis and subsequent formation of stones, casts, and sludge. Some cases of posttransplant biliary stricturing are not IC but are a sequela of reflux cholangitis seen with choledochojejunal anastomosis. Other biliary findings in the posttransplant liver can be explained by sphincter of Oddi dysfunction that results from denervation. The authors describe and comprehensively categorize the various IC types and their imaging patterns at MRI and MR cholangiopancreatography, review the prognostic significance of these imaging patterns, and discuss imaging features of additional biliary complications associated with IC after DCD liver transplant. ©RSNA, 2024 Supplemental material is available for this article.
The invention discloses bacillus beijerinus OUC-BV1 and application thereof in preparation of aquatic pathogenic bacteria inhibitors, and belongs to the technical field of microorganisms. The Bacillus belicus OUC-BV1 is classified and named as Bacillus belicus (Bacillusvelezensis), and is stored in China general microbiological culture Collection center (CGMCC NO. 26580), and the preservation date is: 2023, 02, 20. The bacillus beijerinus OUC-BV1 is applied to preparation of aquatic pathogenic bacteria inhibitors. The invention also discloses an aquatic pathogenic bacteria inhibitor. The bacillus berryis OUC-BV1 has strong antibacterial activity, general antibacterial activity, high temperature resistance and potential application value and huge market demand in the fields of aquaculture and feed replacement resistance, and is expected to be developed into a natural antibiotic product.